Sanofi: Oddo still a buyer
(CercleFinance.com) - Oddo maintains its Outperform rating on Sanofi shares, with an unchanged target price of 105 euros.
The broker considers the positive results of the trial evaluating Dupixent in chronic bronchitis in smokers (COPD) as "extremely positive for the group" .
The analyst states that all primary and secondary endpoints were met in this trial, including: i/ a statistically significant reduction (30%) in exacerbations vs. placebo, ii/ a significant improvement in lung function, and iii/ an improvement in patient quality of life.
With Dupixent and itepekimab, Sanofi has the capacity to address the COPD market. This second active ingredient is currently in phase III and results are expected in 2025 (initially anticipated at the end of 2024 in our opinion), Oddo says.
With sales estimated at an additional E2bn in 2029 by the consensus, the impact on EPS should be between 3% to 5% for this end of decade, the broker estimates.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker considers the positive results of the trial evaluating Dupixent in chronic bronchitis in smokers (COPD) as "extremely positive for the group" .
The analyst states that all primary and secondary endpoints were met in this trial, including: i/ a statistically significant reduction (30%) in exacerbations vs. placebo, ii/ a significant improvement in lung function, and iii/ an improvement in patient quality of life.
With Dupixent and itepekimab, Sanofi has the capacity to address the COPD market. This second active ingredient is currently in phase III and results are expected in 2025 (initially anticipated at the end of 2024 in our opinion), Oddo says.
With sales estimated at an additional E2bn in 2029 by the consensus, the impact on EPS should be between 3% to 5% for this end of decade, the broker estimates.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.